Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS proposes ASP+4% for hospital outpatient drugs

Executive Summary

CMS is proposing to lower the rate at which hospital outpatient drugs are reimbursed from the current average sales price plus 5 percent to ASP plus 4 percent for 2009. According to the outpatient prospective payment system proposed rule for 2009, released July 3, CMS is proposing "to continue our policy of making a combined payment for the acquisition and pharmacy overhead costs of separately payable drugs and biologicals at an equivalent average ASP-based amount calculated based on our standard methodology of estimating drug costs from claims." The agency added that ASP plus 4 percent "is the best currently available proxy for average hospital acquisition cost and associated pharmacy overhead cost.
Advertisement

Related Content

Increase In Pay For Part B Hospital Outpatient Drugs Needed, Groups Tell CMS
Eleven Drugs Lose Medicare Part B Pass-Through Status In 2009 Proposal
Advertisement
UsernamePublicRestriction

Register

PS049832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel